Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma
This study aims to evaluate the efficacy of Camrelizumab with neoadjuvant chemotherapy for resectable thoracic esophageal squamous cell carcinoma
Esophageal Squamous Cell Carcinoma
DRUG: Camrelizumab|DRUG: Paclitaxel for Injection (Albumin Bound)|DRUG: Carboplatin
Pathologic complete remission (PCR), 12 weeks|Major Pathologic Response (MPR), 12 weeks
Overall Survival (OS), 5 years|Event Free Survival（EFS）, 5 years
EQ-5D-3L questionnaire, 5 years|FACT-E questionnaire, Functional Assessment of Cancer Therapy for patients with esophageal cancer questionnaire - version 4 (FACT-E), 5 years
This study aims to evaluate the efficacy of Camrelizumab with neoadjuvant chemotherapy for resectable thoracic esophageal squamous cell carcinoma